Monday, August 2, 2021
CB Insights lists Ractigen as one of the leading companies in China's RNA industry.
[August 2ed, 2021] According to an article published by CB Insights China, Ractigen Therapeutics is listed as one of the 9 RNA companies that can influence the future of the RNA therapeutics industry in China. This is the second time that Ractigen was mentioned by CB Insights China. The agency listed Ractigen as one of the leading companies in RNA therapeutics in China in 2020.
Based on the DPTC system (Depth, Popularity, Tendency, Collaboration), CB Insights China selected 9 RNA leading companies with core technologies and capabilities to influence the future by evaluating the company’s strength, influence, development trends and partnership.
“In just a few decades from the discovery to commercialization, RNA therapy has shown enormous potential” said CB Insights. As one of the pioneers of the saRNA therapeutic field and the first company developing this technology in China, Ractigen recently closed a round of 120 million RMB series A funding and has initiated more than 10 pipeline drug programs with full market rights.”